Targeting oncogenic mutant p53 for cancer therapy

Frontiers in Oncology

Volumn 5, Issue DEC, 2015, Pages

  Parrales, Alejandro ^a   Iwakuma, Tomoo ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer therapy; Compounds; Depletion; Dominant negative; Gain of function; Mutant p53; Oncogenes; Reactivation

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ANTINEOPLASTIC AGENT; ARSENIC DERIVATIVE; CHETOMIN; CYTOCHROME C; DEPSIPEPTIDE; DISULFIRAM; GAMBOGIC ACID; GANETESPIB; GELDANAMYCIN; METALLOCHAPERONE; NSC59984; NSC652287; P53R3; PK7088; PROTEIN P53; ROMIDEPSIN; SCH529074; SPAUTIN 1; STICTIC ACID; STIMA 1; TANESPIMYCIN; UNCLASSIFIED DRUG; VORINOSTAT; YK 3 237;

APOPTOSIS; CANCER INHIBITION; CANCER THERAPY; CELL DEATH; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; DNA BINDING; ENZYME REACTIVATION; HUMAN; MISSENSE MUTATION; NONHUMAN; OSTEOSARCOMA; PROTEIN CROSS LINKING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FOLDING; RADIOSENSITIVITY; REVIEW; TUMOR GROWTH; UPREGULATION;

EID: 84954480179     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00288     Document Type: Review

References (132)

1. Lane D, Levine A. p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol (2010) 2:a000893. doi: 10.1101/cshperspect.a000893.
2. Levav-Cohen Y, Goldberg Z, Tan KH, Alsheich-Bartok O, Zuckerman V, Haupt S, et al. The p53-Mdm2 loop: a critical juncture of stress response. Subcell Biochem (2014) 85:161-86. doi:10.1007/978-94-017-9211-0_9.
3. Vaseva AV, Moll UM. The mitochondrial p53 pathway. Biochim Biophys Acta (2009) 1787:414-20. doi:10.1016/j.bbabio.2008.10.005.
4. Pant V, Lozano G. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev (2014) 28:1739-51. doi:10.1101/gad.247452.114.
5. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol (2013) 15:2-8. doi:10.1038/ncb2641.
6. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer (2011) 2:466-74. doi:10.1177/1947601911408889.
7. Rivlin N, Koifman G, Rotter V. p53 orchestrates between normal differentiation and cancer. Semin Cancer Biol (2015) 32:10-7. doi:10.1016/j.semcancer.2013.12.006.
8. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu Rev Biochem (2008) 77:557-82. doi:10.1146/annurev.biochem.77.060806.091238.
9. Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther (2011) 18:2-11. doi:10.1038/cgt.2010.63.
10. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 22:1337-44. doi:10.1101/gad.1662908.
11. Cavenee WK, Scrable HJ, James CD. Molecular genetics of human cancer predisposition and progression. Mutat Res (1991) 247:199-202. doi:10.1016/0027-5107(91)90015-G.
12. Gonzalez MV, Pello MF, Lopez-Larrea C, Suarez C, Menendez MJ, Coto E. Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. Clin Cancer Res (1995) 1:1043-9.
13. Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, et al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature (2015) 523:352-6. doi:10.1038/nature14430.
14. Masciarelli S, Fontemaggi G, Di Agostino S, Donzelli S, Carcarino E, Strano S, et al. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells. Oncogene (2014) 33:1601-8. doi:10.1038/onc.2013.106.
15. Weisz L, Oren M, Rotter V. Transcription regulation by mutant p53. Oncogene (2007) 26:2202-11. doi:10.1038/sj.onc.1210294.
16. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 148:244-58. doi:10.1016/j.cell.2011.12.017.
17. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science (1999) 286:2507-10. doi:10.1126/science.286.5449.2507.
18. Zhang W, Guo XY, Hu GY, Liu WB, Shay JW, Deisseroth AB. A temperature-sensitive mutant of human p53. EMBO J (1994) 13:2535-44.
19. Selivanova G, Kawasaki T, Ryabchenko L, Wiman KG. Reactivation of mutant p53: a new strategy for cancer therapy. Semin Cancer Biol (1998) 8:369-78. doi:10.1006/scbi.1998.0099.
20. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci U S A (2002) 99:937-42. doi:10.1073/pnas.241629998.
21. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med (1997) 3:632-8. doi:10.1038/nm0697-632.
22. Nikolova PV, Wong KB, DeDecker B, Henckel J, Fersht AR. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J (2000) 19:370-8. doi:10.1093/emboj/19.3.370.
23. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med (2002) 8:282-8. doi:10.1038/nm0302-282.
24. Liu WL, Midgley C, Stephen C, Saville M, Lane DP. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein. J Mol Biol (2001) 313:711-31. doi:10.1006/jmbi.2001.5082.
25. Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR, et al. CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest (2007) 117:3753-64. doi:10.1172/JCI32481.
26. Tanner S, Barberis A. CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity. J Negat Results Biomed (2004) 3:5. doi:10.1186/1477-5751-3-5.
27. Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene (2002) 21:2119-29. doi:10.1038/sj.onc.1205362.
28. Zache N, Lambert JM, Rokaeus N, Shen J, Hainaut P, Bergman J, et al. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol (2008) 2:70-80. doi:10.1016/j.molonc.2008.02.004.
29. Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell (2009) 15:376-88. doi:10.1016/j.ccr.2009.03.003.
30. Lambert JM, Moshfegh A, Hainaut P, Wiman KG, Bykov VJ. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene (2010) 29:1329-38. doi:10.1038/onc.2009.425.
31. Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem (2005) 280:30384-91. doi:10.1074/jbc. M501664200.
32. Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle (2010) 9:1847-55. doi:10.4161/cc.9.9.11545.
33. Burmakin M, Shi Y, Hedstrom E, Kogner P, Selivanova G. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res (2013) 19:5092-103. doi:10.1158/1078-0432.CCR-12-2211.
34. Blanden AR, Yu X, Wolfe AJ, Gilleran JA, Augeri DJ, O'Dell RS, et al. Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore. Mol Pharmacol (2015) 87:825-31. doi:10.1124/mol.114.097550.
35. Yu X, Vazquez A, Levine AJ, Carpizo DR. Allele-specific p53 mutant reactivation. Cancer Cell (2012) 21:614-25. doi:10.1016/j.ccr.2012.03.042.
36. Yu X, Blanden AR, Narayanan S, Jayakumar L, Lubin D, Augeri D, et al. Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget (2014) 5:8879-92. doi:10.18632/oncotarget.2432.
37. Hiraki M, Hwang SY, Cao S, Ramadhar TR, Byun S, Yoon KW, et al. Small-molecule reactivation of mutant p53 to wild-type-like p53 through the p53-Hsp40 regulatory axis. Chem Biol (2015) 22:1206-16. doi:10.1016/j.chembiol.2015.07.016.
38. Liu X, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J, et al. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res (2013) 41:6034-44. doi:10.1093/nar/gkt305.
39. Wassman CD, Baronio R, Demir O, Wallentine BD, Chen CK, Hall LV, et al. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat Commun (2013) 4:1407. doi:10.1038/ncomms2361.
40. Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, et al. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ (2008) 15:718-29. doi:10.1038/sj.cdd.4402301.
41. Demma M, Maxwell E, Ramos R, Liang L, Li C, Hesk D, et al. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J Biol Chem (2010) 285:10198-212. doi:10.1074/jbc. M109.083469.
42. Pluquet O, North S, Richard MJ, Hainaut P. Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity. Biochem Pharmacol (2003) 65:1129-37. doi:10.1016/S0006-2952(02)01655-6.
43. Pluquet O, North S, Bhoumik A, Dimas K, Ronai Z, Hainaut P. The cytoprotective aminothiol WR1065 activates p53 through a non-genotoxic signaling pathway involving c-Jun N-terminal kinase. J Biol Chem (2003) 278:11879-87. doi:10.1074/jbc. M207396200.
44. Shen H, Chen ZJ, Zilfou JT, Hopper E, Murphy M, Tew KD. Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. J Pharmacol Exp Ther (2001) 297:1067-73.
45. North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol Carcinog (2002) 33:181-8. doi:10.1002/mc.10038.
46. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene (2003) 22:8233-45. doi:10.1038/sj.onc.1207198.
47. Rao CV, Patlolla JM, Qian L, Zhang Y, Brewer M, Mohammed A, et al. Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice. Neoplasia (2013) 15:1018-27. doi:10.1593/neo.131256.
48. Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res (2011) 17:2830-41. doi:10.1158/1078-0432.CCR-10-3168.
49. Liang Y, Besch-Williford C, Hyder SM. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Int J Oncol (2009) 35:1015-23. doi:10.3892/ijo_00000416.
50. Zache N, Lambert JM, Wiman KG, Bykov VJ. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell Oncol (2008) 30:411-8. doi:10.3233/CLO-2008-0440.
51. Bykov VJ, Wiman KG. Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett (2014) 588:2622-7. doi:10.1016/j.febslet.2014.04.017.
52. Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM. p53 as a target for the treatment of cancer. Cancer Treat Rev (2014) 40:1153-60. doi:10.1016/j.ctrv.2014.10.004.
53. Saha MN, Chen Y, Chen MH, Chen G, Chang H. Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents. Br J Cancer (2014) 110:2224-31. doi:10.1038/bjc.2014.164.
54. Rivera MI, Stinson SF, Vistica DT, Jorden JL, Kenney S, Sausville EA. Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism. Biochem Pharmacol (1999) 57:1283-95. doi:10.1016/S0006-2952(99)00046-5.
55. Nieves-Neira W, Rivera MI, Kohlhagen G, Hursey ML, Pourquier P, Sausville EA, et al. DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. Mol Pharmacol (1999) 56:478-84.
56. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 10:1321-8. doi:10.1038/nm1146.
57. Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell (2009) 15:441-53. doi:10.1016/j.ccr.2009.03.021.
58. Margalit O, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, et al. Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function. Int J cancer (2012) 131:E562-8. doi:10.1002/ijc.26441.
59. Pintus SS, Ivanisenko NV, Demenkov PS, Ivanisenko TV, Ramachandran S, Kolchanov NA, et al. The substitutions G245C and G245D in the Zn(2+)-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain. J Biomol Struct Dyn (2013) 31:78-86. doi:10.1080/07391102.2012.691364.
60. Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, et al. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle (2011) 10:1679-89. doi:10.4161/cc.10.10.15642.
61. Kung AL, ZabludoffSD, France DS, Freedman SJ, Tanner EA, Vieira A, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell (2004) 6:33-43. doi:10.1016/j.ccr.2004.06.009.
62. Staab A, Loeffler J, Said HM, Diehlmann D, Katzer A, Beyer M, et al. Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer (2007) 7:213. doi:10.1186/1471-2407-7-213.
63. Kessler J, Hahnel A, Wichmann H, Rot S, Kappler M, Bache M, et al. HIF-1alpha inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC Cancer (2010) 10:605. doi:10.1186/1471-2407-10-605.
64. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A (2008) 105:10360-5. doi:10.1073/pnas.0805326105.
65. Lukashchuk N, Vousden KH. Ubiquitination and degradation of mutant p53. Mol Cell Biol (2007) 27:8284-95. doi:10.1128/MCB.00050-07.
66. Blagosklonny MV, Toretsky J, Neckers L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene (1995) 11:933-9.
67. Egorin MJ, Rosen DM, WolffJH, Callery PS, Musser SM, Eiseman JL. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res (1998) 58:2385-96.
68. Wang C, Chen J. Phosphorylation and hsp90 binding mediate heat shock stabilization of p53. J Biol Chem (2003) 278:2066-71. doi:10.1074/jbc. M206697200.
69. Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F, et al. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res (2011) 9:577-88. doi:10.1158/1541-7786.MCR-10-0534.
70. Blagosklonny MV. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle (2005) 4:1693-8. doi:10.4161/cc.4.12.2259.
71. Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ (2011) 18:1904-13. doi:10.1038/cdd.2011.71.
72. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene (2007) 26:1351-6. doi:10.1038/sj.onc.1210204.
73. Yan W, Zhang Y, Zhang J, Liu S, Cho SJ, Chen X. Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression. J Biol Chem (2011) 286:17478-86. doi:10.1074/jbc. M111.231639.
74. Yan W, Jung YS, Zhang Y, Chen X. Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase. PLoS One (2014) 9:e103497. doi:10.1371/journal.pone.0103497.
75. Wang J, Zhao Q, Qi Q, Gu HY, Rong JJ, Mu R, et al. Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP. J Cell Biochem (2011) 112:509-19. doi:10.1002/jcb.22941.
76. Vakifahmetoglu-Norberg H, Kim M, Xia HG, Iwanicki MP, Ofengeim D, ColoffJL, et al. Chaperone-mediated autophagy degrades mutant p53. Genes Dev (2013) 27:1718-30. doi:10.1101/gad.220897.113.
77. Vakifahmetoglu-Norberg H, Yuan J. A degradative detour for mutant TP53. Autophagy (2013) 9:2158-60. doi:10.4161/auto.26338.
78. Yi YW, Kang HJ, Kim HJ, Kong Y, Brown ML, Bae I. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget (2013) 4:984-94. doi:10.18632/oncotarget.1070.
79. Zhang S, Zhou L, Hong B, van den Heuvel AP, Prabhu VV, Warfel NA, et al. Small-molecule NSC59984 restores p53 pathway signaling and antitumor effects against colorectal cancer via p73 activation and degradation of mutant p53. Cancer Res (2015) 75:3842-52. doi:10.1158/0008-5472.CAN-13-1079.
80. Paranjpe A, Srivenugopal KS. Degradation of NF-kappaB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and-nitrosylating drugs in human tumor cells. Carcinogenesis (2013) 34:990-1000. doi:10.1093/carcin/bgt032.
81. Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, et al. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Ann Oncol (2015) 26:1741-8. doi:10.1093/annonc/mdv220.
82. Goyal L, Wadlow RC, Blaszkowsky LS, Wolpin BM, Abrams TA, McCleary NJ, et al. A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs (2015) 33:128-37. doi:10.1007/s10637-014-0164-8.
83. Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, et al. A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer (2014) 14:154-60. doi:10.1016/j.clbc.2013.12.012.
84. Yan W, Liu S, Xu E, Zhang J, Zhang Y, Chen X, et al. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene (2013) 32:599-609. doi:10.1038/onc.2012.81.
85. Beauchamp EM, Uren A. A new era for an ancient drug: arsenic trioxide and Hedgehog signaling. Vitam Horm (2012) 88:333-54. doi:10.1016/B978-0-12-394622-5.00015-8.
86. Jiang W, Wang XW, Unger T, Forgues M, Kim JW, Hussain SP, et al. Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line. Int J Cancer (2010) 127:1011-20. doi:10.1002/ijc.25118.
87. Hughes MF, Beck BD, Chen Y, Lewis AS, Thomas DJ. Arsenic exposure and toxicology: a historical perspective. Toxicol Sci (2011) 123:305-32. doi:10.1093/toxsci/kfr184.
88. Gu H, Wang X, Rao S, Wang J, Zhao J, Ren FL, et al. Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Mol Cancer Ther (2008) 7:3298-305. doi:10.1158/1535-7163.MCT-08-0212.
89. Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell (2011) 147:223-34. doi:10.1016/j.cell.2011.08.037.
90. Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell (2010) 140:384-96. doi:10.1016/j.cell.2009.12.032.
91. Kong Y, Wang K, Edler MC, Hamel E, Mooberry SL, Paige MA, et al. A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent. Bioorg Med Chem (2010) 18:971-7. doi:10.1016/j.bmc.2009.11.003.
92. Kona FR, Buac D, Burger A M. Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies. Curr Cancer Drug Targets (2011) 11:338-46. doi:10.2174/156800911794519798.
93. Nechushtan H, Hamamreh Y, Nidal S, Gotfried M, Baron A, Shalev YI, et al. A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer. Oncologist (2015) 20:366-7. doi:10.1634/theoncologist.2014-0424.
94. Petersen EN. The pharmacology and toxicology of disulfiram and its metabolites. Acta Psychiatr Scand Suppl (1992) 369:7-13. doi:10.1111/j.1600-0447.1992.tb03309.x.
95. Mathieu C, Duval R, Xu X, Rodrigues-Lima F, Dupret JM. Effects of pesticide chemicals on the activity of metabolic enzymes: focus on thiocarbamates. Expert Opin Drug Metab Toxicol (2015) 11:81-94. doi:10.1517/17425255.2015.975691.
96. Davies KJ. Degradation of oxidized proteins by the 20S proteasome. Biochimie (2001) 83:301-10. doi:10.1016/S0300-9084(01)01250-0.
97. Velu CS, Niture SK, Doneanu CE, Pattabiraman N, Srivenugopal KS. Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. Biochemistry (2007) 46:7765-80. doi:10.1021/bi700425y.
98. Yusuf MA, Chuang T, Bhat GJ, Srivenugopal KS. Cys-141 glutathionylation of human p53: studies using specific polyclonal antibodies in cancer samples and cell lines. Free Radic Biol Med (2010) 49:908-17. doi:10.1016/j.freeradbiomed.2010.06.020.
99. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 2:a001008. doi:10.1101/cshperspect.a001008.
100. Micale L, Augello B, Maffeo C, Selicorni A, Zucchetti F, Fusco C, et al. Molecular analysis, pathogenic mechanisms, and readthrough therapy on a large cohort of Kabuki syndrome patients. Hum Mutat (2014) 35:841-50. doi:10.1002/humu.22547.
101. Floquet C, Deforges J, Rousset JP, Bidou L. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res (2011) 39:3350-62. doi:10.1093/nar/gkq1277.
102. Martin L, Grigoryan A, Wang D, Wang J, Breda L, Rivella S, et al. Identification and characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress nonsense p53 mutations. Cancer Res (2014) 74:3104-13. doi:10.1158/0008-5472.CAN-13-2235.
103. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater (2013) 12:967-77. doi:10.1038/nmat3765.
104. Lim LY, Vidnovic N, Ellisen LW, Leong CO. Mutant p53 mediates survival of breast cancer cells. Br J Cancer (2009) 101:1606-12. doi:10.1038/sj.bjc.6605335.
105. Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene (2006) 25:7305-10. doi:10.1038/sj.onc.1209735.
106. Zhu H, Mao Q, Lin Y, Yang K, Xie L. RNA interference targeting mutant p53 inhibits growth and induces apoptosis in DU145 human prostate cancer cells. Med Oncol (2011) 28(Suppl 1):S381-7. doi:10.1007/s12032-010-9679-9.
107. Zhu HB, Yang K, Xie YQ, Lin YW, Mao QQ, Xie LP. Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World J Surg Oncol (2013) 11:22. doi:10.1186/1477-7819-11-22.
108. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchenio T, Lozano G, et al. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A (2002) 99:14849-54. doi:10.1073/pnas.222406899.
109. Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E, et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A (2008) 105:6302-7. doi:10.1073/pnas.0802091105.
110. Shimoyama S. Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. Cancer Chemother Pharmacol (2011) 67:729-39. doi:10.1007/s00280-011-1583-2.
111. Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol (2014) 16:357-66. doi:10.1038/ncb2936.
112. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer (2005) 5:689-98. doi:10.1038/nrc1691.
113. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst (1996) 88:956-65. doi:10.1093/jnci/88.14.956.
114. Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A (2009) 106:3964-9. doi:10.1073/pnas.0813333106.
115. Wang Y, Li J, Booher RN, Kraker A, Lawrence T, Leopold WR, et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res (2001) 61:8211-7.
116. Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, et al. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer (2014) 84:161-7. doi:10.1016/j.lungcan.2014.02.011.
117. Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol (2015) 16:447-56. doi:10.1016/S1470-2045(15)70056-2.
118. Yoo C, Ryu MH, Na YS, Ryoo BY, Lee CW, Maeng J, et al. Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer. Invest New Drugs (2014) 32:271-8. doi:10.1007/s10637-013-9983-2.
119. Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood (2013) 121:3095-102. doi:10.1182/blood-2012-11-466862.
120. Efficace F, Mandelli F, Avvisati G, Cottone F, Ferrara F, Di Bona E, et al. Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes. J Clin Oncol (2014) 32:3406-12. doi:10.1200/JCO.2014.55.3453.
121. Qu FL, Hao XZ, Qin SK, Liu JW, Sui GJ, Chen Q, et al. [Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma]. Zhonghua Zhong Liu Za Zhi (2011) 33:697-701.
122. Verma S, Stewart DJ, Maroun JA, Nair RC. A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram. Am J Clin Oncol (1990) 13:119-24. doi:10.1097/00000421-199004000-00007.
123. Karlsson R, Kullman-Magnusson M, Hamalainen MD, Remaeus A, Andersson K, Borg P, et al. Biosensor analysis of drug-target interactions: direct and competitive binding assays for investigation of interactions between thrombin and thrombin inhibitors. Anal Biochem (2000) 278:1-13. doi:10.1006/abio.1999.4406.
124. Lamos SM, Krusemark CJ, McGee CJ, Scalf M, Smith LM, Belshaw PJ. Mixed isotope photoaffinity reagents for identification of small-molecule targets by mass spectrometry. Angew Chem Int Ed Engl (2006) 45:4329-33. doi:10.1002/anie.200600743.
125. Lomenick B, Hao R, Jonai N, Chin RM, Aghajan M, Warburton S, et al. Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci U S A (2009) 106:21984-9. doi:10.1073/pnas.0910040106.
126. Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundback T, Nordlund P, et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc (2014) 9:2100-22. doi:10.1038/nprot.2014.138.
127. Lammens CR, Bleiker EM, Aaronson NK, Wagner A, Sijmons RH, Ausems MG, et al. Regular surveillance for Li-Fraumeni syndrome: advice, adherence and perceived benefits. Fam Cancer (2010) 9:647-54. doi:10.1007/s10689-010-9368-z.
128. Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. Transl Oncol (2010) 3:1-12. doi:10.1593/tlo.09250.
129. Khoo KH, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov (2014) 13:217-36. doi:10.1038/nrd4236.
130. Tongyang L, Haiqiang G, Meiyan Z, Yingze H, Shuting J, Ying L, et al. [Synthetic lethal genes to mutant p53]. Yi Chuan (2015) 37:321-6. doi:10.16288/j.yczz.14-277.
131. Shaheen M, Allen C, NickoloffJA, Hromas R. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood (2011) 117:6074-82. doi:10.1182/blood-2011-01-313734.
132. Wang X, Simon R. Identification of potential synthetic lethal genes to p53 using a computational biology approach. BMC Med Genomics (2013) 6:30. doi:10.1186/1755-8794-6-30.